Chemours Financials
CC Stock | USD 14.63 0.03 0.21% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 11.8 | 7.2103 |
|
| |||||
Current Ratio | 1.33 | 1.6783 |
|
|
Investors should never underestimate Chemours' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Chemours' cash flow, debt, and profitability to make informed and accurate decisions about investing in Chemours Co.
Cash And Equivalents |
|
Chemours | Select Account or Indicator |
Understanding current and past Chemours Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Chemours' financial statements are interrelated, with each one affecting the others. For example, an increase in Chemours' assets may result in an increase in income on the income statement.
Please note, the presentation of Chemours' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemours' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Chemours' management manipulating its earnings.
Chemours Stock Summary
Chemours competes with International Flavors, Air Products, PPG Industries, Linde Plc, and LyondellBasell Industries. The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. Chemours operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. It employs 6400 people.Specialization | Basic Materials, Specialty Chemicals |
Instrument | USA Stock View All |
Exchange | New York Stock Exchange |
ISIN | US1638511089 |
CUSIP | 163851108 |
Location | Delaware; U.S.A |
Business Address | 1007 Market Street, |
Sector | Chemicals |
Industry | Materials |
Benchmark | Dow Jones Industrial |
Website | www.chemours.com |
Phone | 302 773 1000 |
Currency | USD - US Dollar |
Chemours Key Financial Ratios
Return On Equity | 0.13 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.03 % | ||||
Price To Sales | 0.38 X | ||||
Revenue | 5.78 B |
Chemours Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 7.1B | 7.6B | 7.6B | 8.3B | 7.5B | 7.5B | |
Other Current Liab | 449M | 545M | 475M | 1.2B | 563M | 537.9M | |
Other Liab | 751M | 626M | 707M | 854M | 982.1M | 711.9M | |
Accounts Payable | 820M | 1.2B | 1.2B | 1.1B | 1.1B | 1.1B | |
Other Assets | 292M | 405M | 547M | 725M | 833.8M | 424.1M | |
Long Term Debt | 4.0B | 3.7B | 3.6B | 4.0B | 4.1B | 3.3B | |
Net Receivables | 511M | 720M | 626M | 610M | 770M | 603.4M | |
Inventory | 939M | 1.1B | 1.4B | 1.4B | 1.5B | 1.2B | |
Other Current Assets | 156M | 150M | 82M | 670M | 71M | 67.5M | |
Total Liab | 6.3B | 6.5B | 6.5B | 7.5B | 6.9B | 6.1B | |
Total Current Assets | 2.6B | 3.3B | 3.2B | 3.8B | 3.0B | 3.1B | |
Short Term Debt | 78M | 84M | 141M | 106M | 54M | 93.6M | |
Intangible Assets | 21M | 14M | 6M | 3M | 2.7M | 2.6M | |
Net Tangible Assets | 515M | 646M | 973M | 992M | 892.8M | 710.5M | |
Retained Earnings | 1.3B | 1.7B | 2.2B | 1.8B | 1.7B | 1.2B | |
Cash | 1.1B | 1.5B | 1.1B | 1.2B | 713M | 1.1B | |
Short Long Term Debt | 134M | 21M | 25M | 51M | 54M | 43.1M | |
Net Debt | 3.2B | 2.5B | 2.7B | 3.1B | 3.6B | 3.3B | |
Long Term Debt Total | 4.0B | 4.0B | 3.7B | 3.6B | 3.2B | 3.1B |
Chemours Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 208M | 210M | 185M | 163M | 264M | 156.6M | |
Total Revenue | 5.0B | 6.3B | 6.8B | 6.0B | 5.8B | 5.0B | |
Gross Profit | 1.1B | 1.4B | 1.6B | 1.3B | 1.2B | 1.2B | |
Operating Income | 509M | 888M | 913M | (92M) | 457M | 555.8M | |
Ebit | 447M | 888M | 913M | (110M) | 391M | 587.6M | |
Research Development | 93M | 107M | 118M | 108M | 109M | 88.1M | |
Ebitda | 767M | 1.2B | 1.2B | 197M | 692M | 816.8M | |
Cost Of Revenue | 3.9B | 5.0B | 5.2B | 4.7B | 4.6B | 3.8B | |
Income Before Tax | 179M | 676M | 741M | (318M) | 127M | 120.7M | |
Net Income | 219M | 608M | 578M | (238M) | 86M | 81.7M | |
Income Tax Expense | (40M) | 68M | 163M | (81M) | 41M | 39.0M | |
Tax Provision | (40M) | 68M | 163M | (81M) | 41M | 28.4M | |
Interest Income | 181M | 213M | 142M | 108M | 97.2M | 131.1M | |
Net Interest Income | (208M) | (210M) | (185M) | (163M) | (264M) | (277.2M) |
Chemours Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | 126M | (202M) | (390M) | 58M | (146M) | (138.7M) | |
Free Cash Flow | 540M | 543M | 447M | 186M | (993M) | (943.4M) | |
Depreciation | 320M | 317M | 291M | 307M | 301M | 315.2M | |
Other Non Cash Items | 399M | 16M | (89M) | (58M) | 44M | 51.1M | |
Capital Expenditures | 267M | 277M | 307M | 370M | 360M | 323.3M | |
Net Income | 219M | 608M | 578M | (238M) | 86M | 81.7M | |
Investments | 27M | (12M) | 3M | (229M) | (353M) | (335.4M) | |
Change In Cash | 162M | 446M | (247M) | 503M | (1.0B) | (991.8M) | |
Net Borrowings | 128M | (136M) | (29M) | (1M) | (900K) | (855K) | |
Change To Netincome | 263M | (76M) | (124M) | (10M) | (11.5M) | (12.1M) | |
Change Receivables | 191M | 175M | (225M) | 91M | 104.7M | 109.9M | |
End Period Cash Flow | 1.1B | 1.6B | 1.3B | 1.8B | 763M | 1.3B |
Chemours Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Chemours's current stock value. Our valuation model uses many indicators to compare Chemours value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chemours competition to find correlations between indicators driving Chemours's intrinsic value. More Info.Chemours Co is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.27 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Chemours Co is roughly 3.67 . At present, Chemours' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chemours' earnings, one of the primary drivers of an investment's value.Chemours Systematic Risk
Chemours' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Chemours volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Chemours correlated with the market. If Beta is less than 0 Chemours generally moves in the opposite direction as compared to the market. If Chemours Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Chemours is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Chemours is generally in the same direction as the market. If Beta > 1 Chemours moves generally in the same direction as, but more than the movement of the benchmark.
Chemours Thematic Clasifications
Chemours Co is part of several thematic ideas from Chemicals to Chemicals Makers. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasChemicals | View | ||
Chemicals Makers | View | ||
Plastics | View | ||
Synthetics | View | ||
Trump Equities | View | ||
SRI Sustainable Growth | View |
Today, most investors in Chemours Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Chemours' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Chemours growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Chemours March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Chemours help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Chemours Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Chemours Co based on widely used predictive technical indicators. In general, we focus on analyzing Chemours Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Chemours's daily price indicators and compare them against related drivers.
Information Ratio | (0.14) | |||
Maximum Drawdown | 18.1 | |||
Value At Risk | (5.03) | |||
Potential Upside | 4.21 |
Complementary Tools for Chemours Stock analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |